JP2016525545A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016525545A5 JP2016525545A5 JP2016529759A JP2016529759A JP2016525545A5 JP 2016525545 A5 JP2016525545 A5 JP 2016525545A5 JP 2016529759 A JP2016529759 A JP 2016529759A JP 2016529759 A JP2016529759 A JP 2016529759A JP 2016525545 A5 JP2016525545 A5 JP 2016525545A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion antibody
- acid sequence
- amino acid
- seq
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000004927 fusion Effects 0.000 claims 21
- 150000001413 amino acids Chemical group 0.000 claims 11
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 8
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 8
- 230000008499 blood brain barrier function Effects 0.000 claims 7
- 210000001218 blood-brain barrier Anatomy 0.000 claims 7
- 101000651201 Homo sapiens N-sulphoglucosamine sulphohydrolase Proteins 0.000 claims 6
- 102100027661 N-sulphoglucosamine sulphohydrolase Human genes 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 5
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 4
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 102000005962 receptors Human genes 0.000 claims 3
- 108020003175 receptors Proteins 0.000 claims 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 102000003746 Insulin Receptor Human genes 0.000 claims 2
- 108010001127 Insulin Receptor Proteins 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical group 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 241000699802 Cricetulus griseus Species 0.000 claims 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 229920002971 Heparan sulfate Polymers 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims 1
- 102000011965 Lipoprotein Receptors Human genes 0.000 claims 1
- 108010061306 Lipoprotein Receptors Proteins 0.000 claims 1
- UGJBHEZMOKVTIM-UHFFFAOYSA-N N-formylglycine Chemical compound OC(=O)CNC=O UGJBHEZMOKVTIM-UHFFFAOYSA-N 0.000 claims 1
- 102000005262 Sulfatase Human genes 0.000 claims 1
- 102000007238 Transferrin Receptors Human genes 0.000 claims 1
- 108010033576 Transferrin Receptors Proteins 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 230000007062 hydrolysis Effects 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 102000005861 leptin receptors Human genes 0.000 claims 1
- 108010019813 leptin receptors Proteins 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000003607 modifier Substances 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000004481 post-translational protein modification Effects 0.000 claims 1
- 108060007951 sulfatase Proteins 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020072208A JP6914392B2 (ja) | 2013-07-22 | 2020-04-14 | Ｃｎｓにおける酵素活性を増大するための方法および組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361857140P | 2013-07-22 | 2013-07-22 | |
| US61/857,140 | 2013-07-22 | ||
| PCT/US2014/038660 WO2015012944A1 (en) | 2013-07-22 | 2014-05-19 | Methods and compositions for increasing enzyme activity in the cns |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020072208A Division JP6914392B2 (ja) | 2013-07-22 | 2020-04-14 | Ｃｎｓにおける酵素活性を増大するための方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016525545A JP2016525545A (ja) | 2016-08-25 |
| JP2016525545A5 true JP2016525545A5 (OSRAM) | 2017-06-29 |
| JP6692293B2 JP6692293B2 (ja) | 2020-05-13 |
Family
ID=51023055
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016529759A Active JP6692293B2 (ja) | 2013-07-22 | 2014-05-19 | Ｃｎｓにおける酵素活性を増大するための方法および組成物 |
| JP2020072208A Active JP6914392B2 (ja) | 2013-07-22 | 2020-04-14 | Ｃｎｓにおける酵素活性を増大するための方法および組成物 |
| JP2021115534A Pending JP2021180658A (ja) | 2013-07-22 | 2021-07-13 | Ｃｎｓにおける酵素活性を増大するための方法および組成物 |
| JP2023153971A Pending JP2024012225A (ja) | 2013-07-22 | 2023-09-20 | Ｃｎｓにおける酵素活性を増大するための方法および組成物 |
| JP2024230169A Pending JP2025041923A (ja) | 2013-07-22 | 2024-12-26 | Ｃｎｓにおける酵素活性を増大するための方法および組成物 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020072208A Active JP6914392B2 (ja) | 2013-07-22 | 2020-04-14 | Ｃｎｓにおける酵素活性を増大するための方法および組成物 |
| JP2021115534A Pending JP2021180658A (ja) | 2013-07-22 | 2021-07-13 | Ｃｎｓにおける酵素活性を増大するための方法および組成物 |
| JP2023153971A Pending JP2024012225A (ja) | 2013-07-22 | 2023-09-20 | Ｃｎｓにおける酵素活性を増大するための方法および組成物 |
| JP2024230169A Pending JP2025041923A (ja) | 2013-07-22 | 2024-12-26 | Ｃｎｓにおける酵素活性を増大するための方法および組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20150023956A1 (OSRAM) |
| EP (2) | EP3024848B1 (OSRAM) |
| JP (5) | JP6692293B2 (OSRAM) |
| AU (2) | AU2014293626A1 (OSRAM) |
| CA (1) | CA2918579C (OSRAM) |
| WO (1) | WO2015012944A1 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008022349A2 (en) | 2006-08-18 | 2008-02-21 | Armagen Technologies, Inc. | Agents for blood-brain barrier delivery |
| EP2997976A1 (en) | 2007-07-27 | 2016-03-23 | Armagen Technologies, Inc. | Methods and compositions for increasing alpha-l-iduronidase activity in the cns |
| JP5873003B2 (ja) | 2009-03-18 | 2016-03-01 | アーメイゲン・テクノロジーズ・インコーポレイテッドＡｒｍａｇｅｎ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． | ＩｇＧデコイ受容体融合タンパク質の血液脳関門送達のための組成物および方法 |
| EP2485761B1 (en) | 2009-10-09 | 2019-02-27 | Armagen, Inc. | Methods and compositions for increasing iduronate 2-sulfatase activity in the cns |
| EP2785378B1 (en) | 2011-12-02 | 2020-05-13 | Armagen, Inc. | Methods and compositions for increasing arylsulfatase a activity in the cns |
| US10538589B2 (en) * | 2015-01-14 | 2020-01-21 | Armagen Inc. | Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU |
| EP3448885A4 (en) | 2016-04-26 | 2020-01-08 | R.P. Scherer Technologies, LLC | ANTIBODY CONJUGATES AND METHOD FOR THE PRODUCTION AND USE THEREOF |
| CA3076369A1 (en) | 2017-10-02 | 2019-04-11 | Denali Therapeutics Inc. | Fusion proteins comprising enzyme replacement therapy enzymes |
| EP3833689A4 (en) * | 2018-08-07 | 2022-05-25 | Armagen, Inc. | METHODS AND COMPOSITIONS FOR INCREASING THE ACTIVITY IN THE CENTRAL NERVOUS SYSTEM OF HEXOSAMINIDASE A, ACID SPHINGOMYELINASE AND PALMITOYL-PROTEIN THIOESTERASE 1 |
| MA71661A (fr) | 2020-10-14 | 2025-05-30 | Denali Therapeutics Inc. | Protéines de fusion comprenant des enzymes sulfoglucosamine sulfohydrolase et méthodes associées |
| KR20230156889A (ko) * | 2022-05-04 | 2023-11-15 | 이뮤노포지 주식회사 | GLP-1, 면역글로불린 Fc, 및 IGF-1을 포함하는 융합단백질 및 이의 용도 |
| WO2023240220A1 (en) * | 2022-06-09 | 2023-12-14 | The University Of North Carolina At Chapel Hill | Aav-sgsh vectors for treatment of mucopolysaccharidosis iiia |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5182107A (en) * | 1989-09-07 | 1993-01-26 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates |
| TW279133B (OSRAM) | 1990-12-13 | 1996-06-21 | Elan Med Tech | |
| US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
| US6060069A (en) | 1991-05-20 | 2000-05-09 | Dura Pharmaceuticals, Inc. | Pulmonary delivery of pharmaceuticals |
| US6195608B1 (en) | 1993-05-28 | 2001-02-27 | Lucent Technologies Inc. | Acoustic highway monitor |
| US5997501A (en) | 1993-11-18 | 1999-12-07 | Elan Corporation, Plc | Intradermal drug delivery device |
| US5656284A (en) | 1995-04-24 | 1997-08-12 | Balkin; Michael S. | Oral transmucosal delivery tablet and method of making it |
| PT851753E (pt) | 1995-09-19 | 2004-04-30 | Fujisawa Pharmaceutical Co | Composicoes em aerossol |
| WO1998054213A2 (en) * | 1997-05-30 | 1998-12-03 | Amgen Inc. | Neurotrophic factor receptors |
| US6016800A (en) | 1997-10-24 | 2000-01-25 | Century; Theodore J. | Intrapulmonary aerosolizer |
| DE69839969D1 (de) | 1997-12-11 | 2008-10-16 | Alza Corp | Vorrichtung zur verbesserung des transdermalen flusses von medikamenten |
| US6348210B1 (en) | 1998-11-13 | 2002-02-19 | Alza Corporation | Methods for transdermal drug administration |
| US6375975B1 (en) | 1998-12-21 | 2002-04-23 | Generex Pharmaceuticals Incorporated | Pharmaceutical compositions for buccal and pulmonary application |
| US6284262B1 (en) | 1999-01-26 | 2001-09-04 | Virgil A. Place | Compact dosage unit for buccal administration of a pharmacologically active agent |
| US7388079B2 (en) | 2002-11-27 | 2008-06-17 | The Regents Of The University Of California | Delivery of pharmaceutical agents via the human insulin receptor |
| US20050142141A1 (en) * | 2002-11-27 | 2005-06-30 | Pardridge William M. | Delivery of enzymes to the brain |
| EP1592786B8 (en) * | 2003-02-11 | 2012-03-21 | Shire Human Genetic Therapies, Inc. | Diagnosis and treatment of multiple sulfatase deficiency and other sulfatase deficiencies using a formylglycine generating enzyme (fge) |
| AU2003286870A1 (en) * | 2003-06-05 | 2005-01-04 | Salk Institute For Biological Studies | Targeting polypeptides to the central nervous system |
| EP2485761B1 (en) * | 2009-10-09 | 2019-02-27 | Armagen, Inc. | Methods and compositions for increasing iduronate 2-sulfatase activity in the cns |
| BR112012033197A2 (pt) * | 2010-06-25 | 2017-06-06 | Shire Human Genetic Therapies | métodos e composições para liberação de cns de n-sulfatase de heparano. |
| KR102188544B1 (ko) * | 2010-11-30 | 2020-12-08 | 제넨테크, 인크. | 저친화도 혈액-뇌 장벽 수용체 항체 및 그의 용도 |
| EP2654800B1 (en) * | 2010-12-22 | 2017-12-06 | Fondazione Telethon | Therapeutic strategies to treat cns pathology in mucopolysaccharidoses |
| EP2785378B1 (en) * | 2011-12-02 | 2020-05-13 | Armagen, Inc. | Methods and compositions for increasing arylsulfatase a activity in the cns |
| EP2854834A4 (en) * | 2012-05-30 | 2016-05-18 | Biostrategies LC | PLANT LENSES AS CARRIER CORRESPONDING AGENTS IN ANIMAL AND HUMAN CELLS |
-
2014
- 2014-05-19 EP EP14733790.1A patent/EP3024848B1/en active Active
- 2014-05-19 AU AU2014293626A patent/AU2014293626A1/en not_active Abandoned
- 2014-05-19 JP JP2016529759A patent/JP6692293B2/ja active Active
- 2014-05-19 US US14/281,803 patent/US20150023956A1/en not_active Abandoned
- 2014-05-19 EP EP20179064.9A patent/EP3730516A1/en active Pending
- 2014-05-19 WO PCT/US2014/038660 patent/WO2015012944A1/en not_active Ceased
- 2014-05-19 CA CA2918579A patent/CA2918579C/en active Active
-
2020
- 2020-01-14 AU AU2020200250A patent/AU2020200250A1/en not_active Abandoned
- 2020-04-14 JP JP2020072208A patent/JP6914392B2/ja active Active
- 2020-06-18 US US16/905,292 patent/US20200308292A1/en not_active Abandoned
-
2021
- 2021-07-13 JP JP2021115534A patent/JP2021180658A/ja active Pending
-
2022
- 2022-06-22 US US17/846,999 patent/US20220348672A1/en not_active Abandoned
-
2023
- 2023-09-20 JP JP2023153971A patent/JP2024012225A/ja active Pending
-
2024
- 2024-12-26 JP JP2024230169A patent/JP2025041923A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016525545A5 (OSRAM) | ||
| JP7195142B2 (ja) | 改善された血清アルブミン結合性免疫グロブリン可変ドメイン | |
| CN107921122B (zh) | 与cd38结合的抗体治疗剂 | |
| JP7663977B2 (ja) | 抗ｐｄ―ｌ１抗体およびその用途 | |
| JP2013507131A5 (OSRAM) | ||
| JP2014511680A5 (OSRAM) | ||
| HRP20150799T1 (hr) | Sastavi i postupci za protutijela protiv komplementnog proteina c5 | |
| RU2018113505A (ru) | Il-8-связывающие антитела и их применения | |
| JP2010502207A5 (OSRAM) | ||
| JP2020500538A5 (OSRAM) | ||
| FI3389699T3 (fi) | Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja | |
| JP2016502515A5 (OSRAM) | ||
| JP2017529097A5 (OSRAM) | ||
| HRP20161740T1 (hr) | Ljudske molekule za vezanje koje su sposobne neutralizirati viruse influence a filogenetske skupine 1 i filogenetske skupine 2, te viruse influence b | |
| JP2011509245A5 (OSRAM) | ||
| JP2017536102A5 (OSRAM) | ||
| JP2015522252A5 (OSRAM) | ||
| FI3137504T3 (fi) | Fcrn:ään sitoutuva vasta-aine autoimmuunisairauksien hoitamista varten | |
| JP2016524463A5 (OSRAM) | ||
| JP2017529870A5 (OSRAM) | ||
| JP2013531993A5 (OSRAM) | ||
| WO2017060322A3 (en) | Ptefb-inhibitor-adc | |
| HRP20161096T1 (hr) | Antigenski vežući proteini specifični za komponentu p serumskog amiloida | |
| JP2014530001A5 (OSRAM) | ||
| JPWO2020059847A5 (OSRAM) |